Clinical Trial

A Study to Test the Long-term Safety and Tolerability of Brivaracetam in Study Participants With Childhood Absence Epilepsy or Juvenile Absence Epilepsy

Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The purpose of the study is to investigate the long-term safety and tolerability of brivaracetam in study participants with childhood absence epilepsy or juvenile absence epilepsy.
Protocol Amendment History 4 changes
critical Trial status changed: Recruiting → Active, Not Recruiting 2026-07-10
notable Enrollment reduced: 120 -> 70 participants 2026-07-10
notable Primary completion moved earlier: 2030-03-01 -> 2029-11-16 2026-07-10
minor Completion moved earlier: 2030-03-01 -> 2029-11-16 2026-07-10
Trial Details
NCT Number NCT06315322
Lead Sponsor UCB Biopharma SRL
Conditions Childhood Absence Epilepsy, Juvenile Absence Epilepsy
Enrollment 70 participants
Start Date 2024-07-10
Primary Completion 2029-11-16 (estimated)
Study Completion 2029-11-16 (estimated)
Updated on ClinicalTrials.gov 2026-08-14